Cargando…
Entrectinib use in a platinum-refractory mucinous ovarian cancer harboring a NTRK3 gene fusion
Ovarian cancer is difficult to treat, and the mucinous epithelial subtype has a particularly poor response to traditional chemotherapy regimens. Entrectinib is a tumor-agnostic tyrosine kinase inhibitor with limited data regarding its use in ovarian cancers, though it demonstrates significant tumor...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10131062/ https://www.ncbi.nlm.nih.gov/pubmed/37122438 http://dx.doi.org/10.1016/j.gore.2023.101187 |